{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:28:48Z","timestamp":1788384528044,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Strategic Research Program for Brain Sciences from the Japan Agency for Medical Research and Development","award":["JSPS KAKENHI"],"award-info":[{"award-number":["JSPS KAKENHI"]}]},{"name":"Strategic Research Program for Brain Sciences from the Japan Agency for Medical Research and Development","award":["20H03606"],"award-info":[{"award-number":["20H03606"]}]},{"name":"JSPS KAKENHI","award":["24K02379"],"award-info":[{"award-number":["24K02379"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"Abstract<\/jats:title>\n \n Importance<\/jats:title>\n The norepinephrine transporter (NET) plays a crucial role in major depressive disorder (MDD). Serotonin and norepinephrine reuptake inhibitors, such as duloxetine, are first-line treatments for MDD. Duloxetine inhibits the reuptake of both serotonin and norepinephrine. However, its precise mechanism, particularly regarding NET occupancy and changes in transporter availability, remains unclear. Norepinephrine transmission, mediated by NET, may be instrumental in treating MDD. Therefore, NET occupancy could serve as a potential biomarker to evaluate treatment efficacy.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study evaluated duloxetine\u2019s impact on brain NET availability in patients with MDD using positron emission tomography (PET) with (S,S)-[18F]FMeNER-D2 and its correlation with clinical symptoms using the Hamilton Depression Rating Scale (HAM-D).<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Longitudinal study.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Psychiatric hospitals and clinics.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Fifteen patients with MDD.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Duloxetine (20\u201360\u00a0mg daily).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Baseline PET examinations were conducted for all patients, followed by treatment with duloxetine (20\u201360\u00a0mg daily). After 4\u20136\u00a0weeks of duloxetine administration, a second PET examination was performed, and plasma concentrations of duloxetine were measured immediately before and after the second examination using gas chromatography\u2013mass spectrometry. Seven patients showing symptom improvement over the course of time discontinued duloxetine and underwent a third PET examination after a 2-month washout period.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Norepinephrine transporter occupancy by duloxetine was 30%\u201340% across the doses studied. A paired t-test comparing NET availability before and after duloxetine treatment showed no significant differences, suggesting that duloxetine did not significantly alter NET availability in the short term. Further analysis revealed a significant positive correlation between the change in NET availability and HAM-D scores after treatment. Patients with greater reductions in HAM-D scores exhibited more pronounced reductions in NET availability.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n These findings underscore the potential role of NET occupancy by duloxetine in the treatment of MDD and its relationship with clinical outcomes.<\/jats:p>\n <\/jats:sec>\n \n Relevance<\/jats:title>\n Understanding changes in NET and their implications enhances our comprehension of the complex mechanisms behind antidepressants and may reveal new therapeutic targets for MDD and other neuropsychiatric disorders.<\/jats:p>\n <\/jats:sec>\n \n Clinical trial registration number<\/jats:title>\n UMIN000008251.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaf064","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:58:14Z","timestamp":1757505494000},"source":"Crossref","is-referenced-by-count":2,"title":["A longitudinal PET study on changes in brain norepinephrine transporter availability following duloxetine treatment in major depressive disorder"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7536-9708","authenticated-orcid":false,"given":"Sho","family":"Moriguchi","sequence":"first","affiliation":[{"name":"Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST) , Chiba ,","place":["Japan"]},{"name":"Department of Neuropsychiatry, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Takahata","sequence":"additional","affiliation":[{"name":"Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST) , Chiba ,","place":["Japan"]},{"name":"Department of Neuropsychiatry, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumasa","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Center of Neurology and Psychiatry , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Endo","sequence":"additional","affiliation":[{"name":"Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST) , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tagai","sequence":"additional","affiliation":[{"name":"Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST) , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST) , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-1845","authenticated-orcid":false,"given":"Manabu","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kyoto University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Rong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST) , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST) , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"2026031303415414000_ref1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"key":"2026031303415414000_ref2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11033-019-05129-3","article-title":"The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression","volume":"47","author":"Pitsillou","year":"2020","journal-title":"Mol Biol Rep"},{"key":"2026031303415414000_ref3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1176\/appi.ajp.2016.15101334","article-title":"Norepinephrine transporter in major depressive disorder: a PET study","volume":"174","author":"Moriguchi","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2026031303415414000_ref4","doi-asserted-by":"publisher","first-page":"8451","DOI":"10.1523\/JNEUROSCI.17-21-08451.1997","article-title":"Reduced levels of norepinephrine transporters in the locus coeruleus in major depression","volume":"17","author":"Klimek","year":"1997","journal-title":"J Neurosci"},{"key":"2026031303415414000_ref5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/archpsyc.1986.01800100048007","article-title":"Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims","volume":"43","author":"Mann","year":"1986","journal-title":"Arch Gen Psychiatry"},{"key":"2026031303415414000_ref6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0006-3223(02)01728-6","article-title":"Elevated agonist binding to alpha2-adrenoceptors in the locus coeruleus in major depression","volume":"53","author":"Ordway","year":"2003","journal-title":"Biol Psychiatry"},{"key":"2026031303415414000_ref7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jad.2014.06.016","article-title":"Increased \u03b12- and \u03b21-adrenoceptor densities in postmortem brain of subjects with depression: differential effect of antidepressant treatment","volume":"167","author":"Rivero","year":"2014","journal-title":"J Affect Disord"},{"key":"2026031303415414000_ref8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1503\/jpn.120110","article-title":"Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder","volume":"38","author":"Chandley","year":"2013","journal-title":"J Psychiatry Neurosci"},{"key":"2026031303415414000_ref9","volume-title":"StatPearls [Internet]","author":"Hussain","year":"2024"},{"key":"2026031303415414000_ref10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/3-540-29784-7_20","article-title":"The norepinephrine transporter in physiology and disease","volume":"175","author":"B\u00f6nisch","year":"2006","journal-title":"Handb Exp Pharmacol"},{"key":"2026031303415414000_ref11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/164_2018_164","article-title":"Serotonin and norepinephrine reuptake inhibitors","volume":"250","author":"Shelton","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"2026031303415414000_ref12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00213-005-0304-0","article-title":"A dose-finding study of duloxetine based on serotonin transporter occupancy","volume":"185","author":"Takano","year":"2006","journal-title":"Psychopharmacology"},{"key":"2026031303415414000_ref13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","article-title":"Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study","volume":"161","author":"Meyer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"2026031303415414000_ref14","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59 Suppl 20","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2026031303415414000_ref15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","article-title":"Severity classification on the Hamilton Depression Rating Scale","volume":"150","author":"Zimmerman","year":"2013","journal-title":"J Affect Disord"},{"key":"2026031303415414000_ref16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/syn.20031","article-title":"PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain","volume":"53","author":"Schou","year":"2004","journal-title":"Synapse"},{"key":"2026031303415414000_ref17","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2967\/jnumed.108.051292","article-title":"Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2","volume":"49","author":"Arakawa","year":"2008","journal-title":"J Nucl Med"},{"key":"2026031303415414000_ref18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.neuroimage.2007.07.007","article-title":"A fast diffeomorphic image registration algorithm","volume":"38","author":"Ashburner","year":"2007","journal-title":"Neuroimage"},{"key":"2026031303415414000_ref19","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nn1075","article-title":"Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging","volume":"6","author":"Behrens","year":"2003","journal-title":"Nat Neurosci"},{"key":"2026031303415414000_ref20","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.neuroimage.2009.06.012","article-title":"In vivo mapping of the human locus coeruleus","volume":"47","author":"Keren","year":"2009","journal-title":"Neuroimage"},{"key":"2026031303415414000_ref21","doi-asserted-by":"publisher","first-page":"119620","DOI":"10.1016\/j.neuroimage.2022.119620","article-title":"Designing drug occupancy studies with PET neuroimaging: sample size, occupancy ranges and analytical methods","volume":"263","author":"Laurell","year":"2022","journal-title":"Neuroimage"},{"key":"2026031303415414000_ref22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neuroimage.2018.05.017","article-title":"Likelihood estimation of drug occupancy for brain PET studies","volume":"178","author":"Schain","year":"2018","journal-title":"Neuroimage"},{"key":"2026031303415414000_ref23","doi-asserted-by":"publisher","first-page":"104077","DOI":"10.1016\/j.nsa.2024.104077","article-title":"Therapeutic reference range for duloxetine in the treatment of depression revised: a systematic review and meta-analysis","volume":"3","author":"Amann","year":"2024","journal-title":"Neurosci Appl"},{"key":"2026031303415414000_ref24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.neuroimage.2013.08.001","article-title":"Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD","volume":"86","author":"Ding","year":"2014","journal-title":"Neuroimage"},{"key":"2026031303415414000_ref25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1017\/S1461145712001009","article-title":"Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2)","volume":"16","author":"Nogami","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026031303415414000_ref26","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1038\/npp.2008.47","article-title":"Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine","volume":"33","author":"Owens","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"2026031303415414000_ref27","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/ijnp\/pyx069","article-title":"Occupancy of norepinephrine transporter by duloxetine in human brains measured by positron emission tomography with (S,S)-[18F]FMeNER-D2","volume":"20","author":"Moriguchi","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026031303415414000_ref28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00213-010-1824-9","article-title":"Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2","volume":"210","author":"Sekine","year":"2010","journal-title":"Psychopharmacology"},{"key":"2026031303415414000_ref29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1017\/S1461145713001521","article-title":"Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D\u2082","volume":"17","author":"Takano","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026031303415414000_ref30","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1017\/S1461145713000680","article-title":"Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR","volume":"16","author":"Nyberg","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026031303415414000_ref31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ijnp\/pyx066","article-title":"A positron emission tomography study of norepinephrine transporter occupancy and its correlation with symptom response in depressed patients treated with quetiapine XR","volume":"21","author":"Yatham","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026031303415414000_ref32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1600-0447.2011.01815.x","article-title":"Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression","volume":"125","author":"Isacsson","year":"2012","journal-title":"Acta Psychiatr Scand"},{"key":"2026031303415414000_ref33","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1038\/npp.2008.45","article-title":"Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine","volume":"33","author":"Zhao","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"2026031303415414000_ref34","volume-title":"Duloxetine","author":"Dhaliwal","year":"2024"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/10\/pyaf064\/64240839\/pyaf064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/10\/pyaf064\/64240839\/pyaf064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:42:02Z","timestamp":1773387722000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf064\/8251394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf064","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,11]]},"article-number":"pyaf064"}}